Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
November 15, 2021 08:00 ET
|
Recludix Pharma, Inc.
Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underwayNancy Whiting, Pharm.D. -- an industry veteran and one of Fierce Pharma’s Fiercest Women in...